HF
APLS

HRT Financial’s Apellis Pharmaceuticals APLS Stock Holding History

HRT Financial’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-192,488
Closed -$4.83M – 3742
2025
Q4 		$4.83M Sell
192,488
-161,161
-46% -$3.78M 0.02% 799
2025
Q3 		$8M Buy
353,649
+246,449
+230% +$5.75M 0.03% 469
2025
Q2 		$1.85M Buy
+107,200
New +$1.98M 0.01% 958
2024
Q4 		– Sell
-56,423
Closed -$1.63M – 2396
2024
Q3 		$1.63M Buy
+56,423
New +$2.09M 0.01% 972
2024
Q2 		– Sell
-68,575
Closed -$4.03M – 2181
2024
Q1 		$4.03M Sell
68,575
-7,337
-10% -$468K 0.02% 327
2023
Q4 		$4.54M Buy
+75,912
New +$3.85M 0.03% 333
2023
Q3 		– Sell
-309,024
Closed -$28.2M – 2367
2023
Q2 		$28.2M Buy
+309,024
New +$26.7M 0.26% 41
2022
Q1 		– Sell
-32,355
Closed -$1.53M – 3053
2021
Q4 		$1.53M Buy
+32,355
New +$1.27M 0.01% 820
2021
Q3 		– Sell
-6,204
Closed -$392K – 3245
2021
Q2 		$392K Buy
+6,204
New +$320K ﹤0.01% 1968

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

HRT Financial's APLS Position: Q1 2026 in Review

HRT Financial sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 192,488 shares — an estimated $4.83M sold.

HRT Financial first reported a position in APLS in Q2 2021 and held it in 9 quarters. The position peaked at $28.2M in Q2 2023. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • HRT Financial reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 192,488 Apellis Pharmaceuticals shares in Q1 2026, an estimated $4.83M.
  • HRT Financial first reported a position in Apellis Pharmaceuticals in Q2 2021 and held it in 9 quarters.
  • HRT Financial's Apellis Pharmaceuticals position peaked at $28.2M in Q2 2023.
  • 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.